Autophagy links pattern recognition receptors to tumor cell apoptosis

Molecular Therapy

Volumn 17, Issue 11, 2009, Pages 1839-1841

  Vollmer, Jörg ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; DOUBLE STRANDED RNA; FAS LIGAND; IMIQUIMOD; LIPOSOME; MELANOMA ANTIGEN; MELANOMA ANTIGEN 5; PATTERN RECOGNITION RECEPTOR; POLYETHYLENEIMINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN BCL 2; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CELL ACTIVATION; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CYTOKINE RELEASE; DRUG EFFICACY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; INNATE IMMUNITY; LIPOSOMAL GENE DELIVERY SYSTEM; MELANOMA; NONHUMAN; NOTE; REGULATORY MECHANISM; SKIN CANCER; TUMOR CELL; UPREGULATION;

EID: 70449100471     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.241     Document Type: Article

References (17)

1. Vollmer, J and Krieg, A (2008). Mechanisms and therapeutic applications of immune modulatory oligodeoxynucleotide and oligoribonucleotide ligands for Toll-like receptors. In: Crooke, ST (ed). Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. CRC Press: Boca Raton, FL, pp. 747-772.
2. Alexopoulou, L, Holt, AC, Medzhitov, R and Flavell, RA (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
3. Gitlin, L, Barchet, W, Gilfillan, S, Cella, M, Beutler, B, Flavell, RA et al. (2006). Essential role of mda-5 in type I IFN responses to polyriboinosinic:pOlyribocytid ylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 103: 8459-8464.
4. Kato, H, Takeuchi, O, Mikamo-Satoh, E, Hirai, R, Kawai, T, Matsushita, K et al. (2008). Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205: 1601-1610.
5. Schlee, M, Hartmann, E, Coch, C, Wimmenauer, V, Janke, M, Barchet, W et al. (2009). Approaching the RNA ligand for RIG-I? Immunol Rev 227: 66-74.
6. Yi, AK, Hornbeck, P, Lafrenz, DE and Krieg, AM (1996). CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol 157: 4918-4925.
7. Jahrsdorfer, B, Wooldridge, JE, Blackwell, SE, Taylor, CM, Griffith, TS, Link, BK et al. (2005). Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 77: 378-387.
8. Jurk, M, Heil, F, Vollmer, J, Schetter, C, Krieg, AM, Wagner, H et al (2002). Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3: 499.
9. Gaspari, A, Tyring, SK and Rosen, T (2009). Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 8: 467-474.
10. Schon, MP and Schon, M (2006). The small-molecule immune response modifier imiquimod - its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets 10: 69-76.
11. Tormo, D, Checinska, A, Alonso-Curbelo, D, Perez-Guijarro, E, Canon, E, Riveiro-Falkenbach, E et al. (2009). Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16: 103-114.
12. Besch, R, Poeck, H, Hohenauer, T, Senft, D, Hacker, G, Berking, C et al. (2009). Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119: 2399-2411.
13. Delgado, M, Singh, S, De Haro, S, Master, S, Ponpuak, M, Dinkins, C et al. (2009). Autophagy and pattern recognition receptors in innate immunity. Immunol Rev 227: 189-202.
14. Robinson, RA, DeVita, VT, Levy, HB, Baron, S, Hubbard, SP and Levine, AS (1976). A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst 57: 599-602.
15. Cubillos-Ruiz, JR, Engle, X, Scarlett, UK, Martinez, D, Barber, A, Elgueta, R et al. (2009). Polyethylenimine-based siRNA nanocomplexes reprogram tumor associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119: 2231-2244.
16. Pichlmair, A, Schulz, O, Tan, CP, Rehwinkel, J, Kato, H, Takeuchi, O et al. (2009). Activation of MDA5 requires higher order RNA structures generated during virus infection. J Virol, e-pub ahead of print 5 August 2009.
17. Poeck, H, Besch, R, Maihoefer, C, Renn, M, Tormo, D, Morskaya, SS et al. (2008). 5′-triphosphate-siRNA: Turning gene silencing and Rig-I activation against melanoma. Nat Med 14: 1256-1263.